anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Systemic lupus erythematous is a chronic multifactorial autoimmune disease that affects many organs including kidney. Lupus nephritis is a common manifestation characterized by heterogeneous clinical and histopathological finding and often associate with poor progression and despite potent anti-inflammatory and immunosuppressive therapies still end in CKD or ESRD for too many patient. lupus nephritis is an immune complex GN that develop as a frequent complication of SLE. The pathogenesis of lupus nephritis involve a variety of pathogenic mechanisms, intra renal pathomechanisn of SLE related nephritis immune complex formation and classical complement pathway activation. Lupus nephritis doesn\&#39;t develop in the absence of antinuclear antibodies. Circulating polyclonal autoantibodies bind to intrarenal nucleosomes and other autoantigen, which lead to local complement activation , cell injury and subsequent cytokine and chemokine secretion . The current management of lupus nephritis remain based on steroids, cyclophosphamide, azathioprine ,mycophenolate mefetile which are all unselective immunosuppressive drugs, these drugs have proven to be efficient in reducing lupus nephritis disease activity but the long term outcomes of lupus nephritis have not further improved during the last 30 years . Identification of renal survival is mandatory for certain purposes i.e, evaluation of efficacy of different treatment strategies among our patients and factors associated with the survival data as compared with other specialized centers.
1,188,629. Steroid compositions. F. HOFFMANN-LA ROCHE &amp; CO. A.G. 18 July, 1968 [28 July, 1967], No. 34358/68. Heading A5B. Therapeutic compositions for the treatment of disturbances of the normal hormonal equilibrium, for oral administration, comprise a medicament nucleus containing a sulpho-conjugated neutral steroid (wherein the steroid moiety is a C 21 , C 19  or C 18  steroid) coated with a layer which is resistant to gastric juice but which is capable of dissolution in the intestines. The steroid comprises the sulphates (acidic and mixed salts with ammonium, Na, K and Ca) and sulphatides (esters of acidic sulphates wherein the sulpho group is esterified with a non-toxic pharmaceutically acceptable monovalent or polyvalent alcohol e.g. glycerine, palmityl or stearyl alcohol) of non- phenolic steroids e.g. pregnenolone, desoxycorticosterone, progesterone, dehydro-epi-androsterone, testosterone and 19-nortestosterone. The coating may be composed of any conventional material e.g. keratin, shellac, colophony, cellulose acetate phthalate, cellulose acetate succinate, copolymers of styrene and maleic acid anhydride, copolymers of butyl partial ester of maleic acid with styrene and acrylic acid, copolymers of maleic acid anhydride and vinyl methyl ether and of styrene and methacrylic acid. The example relates to a dragee nucleus containing sodium dehydro-epi-androsterone sulphate coated with cellulose acetate phthalate.
The invention comprises compounds of the formula &lt;FORM:1086530/C2/1&gt; in which R and R1 each represents a hydrogen atom or a C1- 4 alkyl or allyl group, or together form a -(CH2)ngroup where n is 4, 5 or 6, and X and Y each represents a hydrogen, chlorine, bromine or fluorine atom or a methyl, ethyl, cyano, trifluoromethyl, hydroxy, nitro, amino C1- 4 alkylamino, di(C1- 4 alkyl)amino, carboxy or methoxy- or ethoxy-carbonyl group; and their acid addition salts with acids having non-toxic anions.  The compounds are prepared by (a) hydrolysing or reducing corresponding 1-acylamino-4-phenyl-bicyclo[2,2,2]-octanes to form the corresponding 1-amino or 1-alkylamino compounds, or (b) ammonolysing or aminolysing methane sulphonic esters of 4-hydroxy -4-phenyl-bicyclo[2,2,2]octanes, or (c) reducing 4 - phenyl - bicyclo[2,2,2]oct - 2 - ene-1 -carboxylic acids or their esters to yield 4-phenyl - bicyclo[2,2,2]octane - 1 - carboxylic acids or esters, if necessary saponifying the esters to the free acids, and converting the acids by the Hofmann, Curtius or Schmidt reaction to 4-phenyl - bicyclo[2,2,2]octane - 1 - amines, or (d) alkylation of 4-phenyl-bicyclo[2,2,2]octane-1 -amines or -alkylamines, e.g. by reaction of alkyl halides or dialkyl sulphates in the presence of a base, or by acylation followed by reduction with lithium aluminium hydride of the resulting N -acyl-amine or N -acyl-N -alkylamine.  In a modification of process (d), compounds of Formula I in which R and R1 together form the divalent group -(CH2)nare made by reacting the primary amine with a dicarboxylic acid anhydride to form a corresponding N carboxyacyl-amine which is reduced and cyclized with lithium aluminium hydride.  Starting materials.-1-Acetamido-4-phenyl-bicyclo[2,2,2,]octane is prepared by reacting 4-hydroxy - 1 - phenyl - bicyclo[2,2,2]octan - 2-one with hydrazine to form the corresponding hydrazone, heating this with hydrazine, diethylene glycol and potassium hydroxide to form 4 - phenyl - bicyclo[2,2,2]octan - 1 - ol and reacting this with acetonitrile.  1-Acylamino-4-(substituted phenyl)-bicyclo[2,2,2]octanes are prepared by nitrating a 1-acylamino-4-phenyl-bicyclo[2,2,2]octane, reducing the nitro compound to the corresponding amino compound, diazotizing the amino compound and replacing the diazo group in the resulting compound by a hydroxy group by heating it in an aqueous solution or by a halogen atom or cyano group by reacting it with a cuprous halide or cuprous cyanide.  A resulting phenol may be alkylated to give the corresponding alkoxy compound, or a resulting nitrile may be hydrolysed to the corresponding carboxylic acid which may be converted to an ester or reacted with sulphur tetrafluoride to replace the carboxy group by a trifluoromethyl group.  If, instead of diazotization, the amino group is acylated and reduced with lithium aluminium hydride the corresponding mono- and di-alkylamino compounds are prepared.  Pharmaceutical compositions having anti-depressant activity, for oral or parenteral administration, comprise a compound of the invention together with a pharmaceutical carrier.
1. Use of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells resulting in the protection from graft rejection by a host&#39;s immune system. 2. Use as claimed in claim 1, wherein the DNA encoding a LAG-3 protein is exogenous. 3. Use as claimed in claim 1, wherein the DNA encoding a LAG-3 protein is endogenous and its expression is activated or modified through the targeted insertion of a regulator sequence and/or an amplifiable gene by homologous recombination. 4. Use as claimed in any of claims 1 to 3, wherein said cells are part of a tissue or organ to be transplanted. 5. Use as claimed in any of claims 1 to 3, wherein said cells are gene therapy host cells. 6. Use as claimed in claim 5, wherein gene therapy is somatic or &#34;ex vivo&#34; gene therapy. 7. Use as claimed in any of claims 1 to 6, wherein said cells are derived from transgenic animals. 8. Use as claimed in any of claims 1 to 7, wherein said cells are selected from myoblasts, fibroblasts, hematopoietic stem cells, embryonic stem cells, foetal liver cells, umbilical vein endothelial cells or CHO cells. 9. Use of a combination of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells and an additional immuno-suppressive agent, such as IL-10. TGFss or Fas ligand resulting in the protection from graft rejection by a host&#39;s immune system. 10. Use as claimed in claim 9, wherein said cells are derived from transgenic animals. 11. Use as claimed in claim 9 or 10, wherein said cells are selected from myoblasts, fibroblasts, hematopoietic stem cells, embryonic stem cells, foetal liver cells, umbilical vein endothelial cells or CHO cells. 12. Use of a combination of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells and the thymidine Kinase (tk) gene to be sensitive to the tk-gancyclovir suicide system resulting in the protection from graft rejection by a host&#39;s immune system. 13. Use as claimed in claim 12, wherein said cells are derived from transgenic animals. 14. Use as claimed in claim 12 or 13, wherein said cells are selected from myoblasts, fibroblasts, hematopoietic stem cells, embryonic stem cells, foetal liver cells, umbilical vein endothelial cells or CHO cells. 15. Use of a combination of genetically engineered eukaryotic cells comprising DNA encoding a transmembrane LAG-3 protein expressed on the surface of said cells in the manufacture of a medicament to induce protection from graft rejection by a host&#39;s immune system.
PURPOSE:To obtain an emetocathartic composition having enhanced antidiarrhea action, reducing a dose, having a little side effects by blending loperamide hydrochloride with &gt;=a fixed amount of a saccharide. CONSTITUTION:Loperamide hydrochloride is blended with &gt;=3,000 times as much saccharide (e.g. white sugar). The concentration of loperamide hydrochloride in a composition is preferably 0.001-0.02wt%. The blend is properly mixed with a generally usable excipient, lubricant, binder, aroma, coloring agent, pH adjuster to give the objective substance. The objective substance is preferably made into a dosage form such as syrup or dry syrup. By blending loperamide hydrochloride with &gt;=3,000 times as much as the saccharide by weight, anti-diarrhea action is obtained with about 1/3 ordinary dose of loperamide hydrochloride.
PROBLEM TO BE SOLVED: To obtain a titanium oxide-containing flaky aluminum oxide having large aspect ratio and a smooth surface by hydrolyzing a mixed aq. solution of a water soluble aluminum salt with a titanium salt, drying by evaporation and by a fused salt treating. SOLUTION: The mixed aq. solution (A) consisting of the water soluble aluminum salt (e.g. aluminum sulfate) with the titanium salt (e.g. titanium trichloride) and the alkali carbonate aq. solution (B) almost equivalent to the water soluble aluminum salt and the titanium salt of the component (A) are prepared. Next, after an alkali metal sulfate and phosphoric acid or a phosphate compound are added into the aq. solution of the component (A) or the component (B) to uniformly dissolve, the component (A) and the component (B) are mixed to form a suspension or gel containing a hydrolyzed product. Next, the suspension or gel is dried by evaporation, fused salt treating at 900-1400 deg.C and the produced solid material is washed with water, filtered and dried.  As a result, the titanium oxide-containing flaky aluminum oxide having 5-60μm average particle diameter &lt;=1μm thickness and an aspect ratio of &gt;=20 is obtained.
PROBLEM TO BE SOLVED: To prepare a cosmetic excellent in warm bathing effects and humectant effects on skin by using a refermentation product obtained by effectively utilizing a by-product formed when producing Sake (a Japanese fermented, mildly alcoholic beverage made from rice) or a waste rejected when producing a Shochu (low-class distilled spirits). SOLUTION: This cosmetic is prepared by formulating a fermentation product obtained by refermenting Sake lees or Shochu distillation by-products. The fermentation product of the Sake lees is obtained by adding water to Sake lees, fermenting the Sake lees at 5-35 deg.C for &gt;=3 days and then filtering the fermentation product under pressure. The fermentation product of the Shochu distillation by-products is obtained by adding saccharides to the Shochu distillation by-products, fermenting the by-products at 5-35 deg.C for &gt;=3 days and filtering the fermentation product under pressure. The liquid fermentation product, its concentrate, etc., thus obtained may directly be used as the cosmetic or an oil, a surfactant, a solvent, a humectant, etc., and may suitable be added thereto. The cosmetic is preferably used as a skin conditioning cosmetic or a bathing agent.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide oral tablet formulations which overcome or improve issues (e.g. insolubility, instability and cracks of tablets) associated with oral conjugated estrogen tablets.  &lt;P&gt;SOLUTION: Oral conjugated estrogen formulations are disclosed and described. In one aspect, this oral formulation may be a tablet having a core and one or more coatings on this core. In addition to conjugated estrogen ingredients, this core may include one or more organic excipients and one or more inorganic excipients. In one aspect, this organic excipients may include less than about 20% (w/w) of a cellulose ingredient, and less than about 50% (w/w) of a sugar ingredient. In another aspect, this inorganic excipients may include less than about 10% (w/w) of a tricalcium phosphate ingredient. In yet another aspect, this formulation does not crack when stored at about 40°C and about 75% relative humidity for about 2 months.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide two kinds of new proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2.  &lt;P&gt;SOLUTION: Each of the new proteins encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by MAb 17C7. One or more of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Synthesized products and both diagnostic and curative methods for the treatment and study of M. catarrhalis are also provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention relates to new lactam compounds, pharmaceutical compositions containing them (especially those for oral or rectal application) and to processes for the preparation of these compounds and compositions. The new compounds have the general formula &lt; IMAGE &gt; (I) wherein X represents a straight or branched alkyl radical with 1 to 4 carbon atoms, preferably a methyl group. The new compounds of formula (I) have sedating-tranquilizing properties. In higher dosages some of them also act as hypno-anesthetics. Moreover the derivative in which X represents the methyl group has anticonvulsant activities. The valuable compounds of formula (I) are prepared in a manner known per se e.g. by reacting an 3-alkyl-3-halogen-2-oxopiperidine (the alkyl having 1-4 carbon atoms) with a metal derivative of 2,3-dihydro-3-oxo-1,2-benzisothiazoldioxid-(1,1) or by reacting an 3-alkyl-3-amino-2-oxopiperidine with o-sulfobenzoic acid dichloride or dibromide or with an o-halomercaptobenzoylhalide, followed by oxydation. Other processes known per se, such as cyclizations to form lactam rings, are also suitable for the preparation of the compounds of formula (I).
PURPOSE:To obtain the subject compound extremely reduced in the leakage of contents by encapsulating a hydrophilic substance in the inner aqueous phase of a polymerizable lipid microsome, polymerizing the lipid constituting the membrane of the microsome, adding a specific saccharide only to the removable outer aqueous phase of the microsome and subsequently lyophilizing the microsome. CONSTITUTION:The membrane component of a polymerizable lipid (e.g. polymerizable phospholipid or polymerizable glucolipid) constituting a microsome containing a hydrophilic substance such as protein, physiologically active peptide, anticancer agent, antibiotic, vitamin, immubopotentiating agent or hormone is polymerized. A saccharide (e.g. sucrose, trehalose or cellobiose) having a mol.wt. of &lt;=1200 is added to the outer aqueous phase of the microsome. The aqueous dispersion of the microsome is lyophilized to obtain a powdery lipid microsome preparation. The preparation is extremely reduced in the leakage of the content from the inner aqueous layer of the lipid microsome, is free from the change in the particle diameter of the lipid microsome and permits to remove the saccharide added as a protecting agent, when again dispersed.
NEW MATERIAL:A compound expressed by formula I (R is H or methyl). EXAMPLE:Benzoylmethyl 2-(2,6-dichloroanilino)phenylacetate. USE:An anti-inflammatory and analgesic agent having little damaging action on stomach mucous membrane. PREPARATION:A compound expressed by formula II or a salt or a reactive functional derivative thereof is reacted with an esterifying agent expressed by formula III in a solvent if necessary under cooling or heating in a closed vessel and/or inert gas atmosphere to give the compound expressed by formula I . In case the compound expressed by formula II is a face acid, the reaction is preferably carried out in the presence of a condensing agent, e.g. N,N&#39;-dicyclohexylcarbodiimide, or base.
The invention relates to arteannuin transdermal patch matrix, a preparation method and arteannuin transdermal patch thereof. The matrix of the patch contains acrylic acid pressure-sensitive adhesive, transdermal accelerating agent and arteannuin medicament. The pressure-sensitive adhesive, the transdermal accelerating agent and the medicament are blended, and then coated and dried to prepare the transdermal patch with viscosity. The patch can make the medicament released stably and prolong half-life; and through  transdermal experiments in vitro and in vivo, permeating amount of arteannuin for full skin of nude mice can reach more than 500 mu g/cm&lt;2&gt; in 24 hours. Transdermal experiments on mouse show that the patch is applied once, and concentration of blood medicament is stable after 96 hours and kept at 100ng/ml. Pharmacodynamical experiments on the nude mice show that after the nude mice are affected by plasmodium, the backs of the nude mice are applied by the patch, the patch is replaced every day in four days continuously, and then the suppression ratio is 15.44 percent after 1 day of patch application and 96.51 percent after 4 days.
The present invention relates to an enhanced and simplified herpes virus amplicon packaging system. The packaging system comprises a herpes virus amplicon vector and a packaging vector. In one embodiment, the packaging vector comprises a bacterial artificial chromosome (BAC) containing the HSV-1 genome. The packaging vector contains an intact pac site but is otherwise rendered packaging defective. The packaging vector can be rendered packaging defective by inserting nucleotides into the pac site, or by otherwise interfering with the capsid&#39;s ability to close, for example, by increasing the size of the DNA fragment upon which the herpes virus genome is cloned. This system can be used to package a wide range of nucleotide sequences (e.g., a therapeutic or antigenic gene) into an empty herpes virus particle taking advantage of the large transgene capacity of herpes viruses. This system can also be used as a vaccine to induce protective immunity against HSV-1, or other complex pathogens.
FIELD: medicine. ^ SUBSTANCE: pharmaceutical composition contains CO2-extract of barbate lichen and CO2- extract of common St. John&#39;s wort in certain ratio. Application of the composition to prepare the drug for treatment of seborrheic skin disease. Application of the pharmaceutical composition to prepare the drug for treatment of seborrheic diseases. The drug represents an intake medical product. Application of the composition to prepare the drug for treatment of skin radiolesions. Application of the composition to prepare the drug for treatment and prevention of skin ageing. ^ EFFECT: clinical effectiveness for seborrheic skin disease, skin radiolesions and acne. ^ 19 cl, 7 dwg, 4 tbl, 10 ex
A method of determining the viability of tissue in a region of an organism comprises the steps of introducing an ATP repleting agent into the region and monitoring the region to determine its effect on T1-201 distribution in the region. The capability of viable tissue to synthesize ATP and increase its ATP stores provides an indication of the viability of the tissue in the region. In a preferred embodiment of the method, ribose, which is a high energy phosphate precursor and an ATP repleting agent, is introduced into heart tissue that is being monitored by T1-201 scintigraphy. The ribose increases the rate and extent of T1-201 distribution in the heart tissue, thereby allowing the determination of viable &#34;stunned&#34; heart tissue. That viable tissue is distinguishable from nonviable tissue is attributed to the capability of the former to synthesize ATP and increase its ATP stores in response to the administration of the ATP repleting agent. Such manipulation of ATP stores in a region of tissue effects a detectable change in T1-201 distribution in that region. The method permits, therefore, the rapid determination of viable heart tissue.R
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition with cells kept dormant or invariant, mitigating pollinosis through highly depositing and adsorbing allergens such as pollen thereonto, to provide an emulsified product thereof, and to provide methods for producing the composition and emulsified product.  &lt;P&gt;SOLUTION: The composition is such as to be obtained by melting dehydrated cells into a hydrophobic solvent. The emulsified product thereof is also provided. Besides, the respective methods for producing the composition and emulsified product are provided. They can be used as food, cosmetics or medical supplies. In the above, the dehydrated cells can be kept dormant by making them lyophilized cells.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Molecular conjugates which facilitate the attachment of macromolecular drugs onto cellular surfaces and their entry into cells are described. The molecular conjugates comprise a macromolecular drug linked to an &#39;&#39;inactivated&#39;&#39; membrane blending agent which inserts into the cellular plasma membrane. The membrane blending agent is inactivated by cleavable linkage to a blocking agent which, until released from the conjugate under appropriate conditions, blocks the ability of the membrane blending agent to insert into the cellular membrane. Upon release of the blocking agent, the membrane blending agent is &#39;&#39;activated&#39;&#39; and the conjugate can be inserted into a cellular plasma membrane. The membrane blending agents can be peptides such as fusogenic or ion channel forming peptides or long chain fatty acids. The blocking agents can be bulky or charged moieties which mask and prevent insertion of the membrane blending agent.
NEW MATERIAL:A compound expressed by formula I [R represents OH, lower alkoxyl, (halogen-substituted)phenol or H; m is an integer 0-7, provided that m is an integer 1-7 when R is H; n is 2 or 3; Xs are adjacent to each other and represent OH or lower alkoxyl]. EXAMPLE:1-(3&#39;,4&#39;-Dihydroxyphenyl)-3-oxo-1-octene. USE:Medicines having inhibitory action on lipoxygenase and useful as remedies and preventives for allergic diseases, asthma, inflammation, etc. The daily dose is 10-300mg orally administered once - individed several portions. PREPARATION:A compound expressed by formula II is reacted with a novel compound expressed by formula III preferably in a solvent such as 1,2-dimethoxyethane in the presence of non-nucleophilic base such as NaOH at -80 deg.C - room temperature for 2-4hr to obtain the compound expressed by formula I. The novel compound expressed by formula III is obtained by reacting a compound expressed by formula IV with a compound expressed by formula V.
Pharmaceutical compsn. for topical application for treating virus diseases of the skin and mucous membranes contains (a) a virustatic cpd. of the antimetabolite type, and (b) an Ag, Bi, Cu or Zn salt, in a conventional carrier plus usual additives. The compsn. is esp. formulated as a gel and the pref. active ingredients are ZnSO4 and beta-5-ethyl-2&#39;-deoxyuridine. Used partic. for treating herpes infections. The metal salts are effective against RNA and DNA viruses; do not induce development of resistant strains; are not teratogenic or mutagenic and do not delay regeneration of affected tissue. They also intensify and extend the activity of (I) allowing smaller doses to be used.